Solius

Executive Summary

Solius is a Seattle-based digital health startup developing medical light therapy devices that replicate the sun's beneficial wavelengths to stimulate vitamin D production and other healing responses in the body. Founded in 2018, the company aims to address metabolic and general health deficiencies through non-pharmaceutical, light-based interventions. While still private and early-stage, Solius's approach taps into growing interest in photobiomodulation and non-invasive therapies. The technology could potentially disrupt traditional vitamin D supplementation and offer new avenues for managing metabolic disorders. However, the company lacks disclosed funding, valuation, or commercial products, indicating it is likely in preclinical or early clinical development. Key risks include regulatory hurdles, clinical proof of efficacy, and market adoption.

Upcoming Catalysts (preview)

• Q2 2026Completion of Phase I clinical trial demonstrating vitamin D synthesis efficacy40% success
• Q4 2026FDA 510(k) clearance for a first-generation light therapy device for metabolic health35% success
• TBDStrategic partnership or licensing deal with a major health system or supplement manufacturer30% success